# Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs

> **Open Intelligence Dossier** · First detected: 2026-11-04 21:00 UTC · Category: Business

## Executive Summary
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
&quot;Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs&quot; is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.


Outlets currently covering the story include FirstWord Pharma, Pharmaceutical Executive, Endpoints News and Bloomberg. PULSE measures a story&#039;s velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE&#039;s extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| FirstWord Pharma | Boehringer in $7B cancer drug development deal with Sino Biopharm | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE8wMmIyckhhTDBQUDVsTjlNVFBlVWdSNm1UbHZWVkJWVUd0aVg3ZkNZOXZQVzBMeHRZTUtHZThhMjNXUkxmYmJNaG9KZ0pqTUFuYkQ4?oc=5) |
| Pharmaceutical Executive | Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4 Agonist to AbbVie | [Source Link](https://news.google.com/rss/articles/CBMivgFBVV95cUxOUlhTNFJMcmVqYkJYa01odWhmWXpNUnIwLUtnUW1XeXZzaXY5VVBsNG1WVmsyYkFFekZmai1LYV9pemVVMXhPdDlmR1dEajZNLUwtZHBIbHZJQnVXTVZsUFh5TUFZTzdBWW0wTENfTmo3cUJuQjlHRHl1cXYtclhWSUdVWHBIclg0TmNIa1F6MlZCM1ctTEtDXzJubVJQR1FFYXd6d2FmZUg3LUZUbE9tMEFtTzl6N1dXc1B4UWVn?oc=5) |
| Endpoints News | Boehringer Ingelheim strikes $7B backloaded ADC, TCE cancer deal with China’s Sino | [Source Link](https://news.google.com/rss/articles/CBMipgFBVV95cUxNVEZFZ0E0Xy1ySk5VLVNua0JsN0lUNXRLdXdPUTVNT1NsNDVPc1p6bXZ6eWRNZFBHWEdpaTdjWjk5NmNxTUdZdkhyRnJDNGIwTXVzd1VMYlRRN0l2VHp5YU9OazBoUWE0Z3hqYlliZzBkSTd0MkdOQ3VTVThPNkVmelB6TXdYamkxX1M2TERNM2RzMUNNNmdBWUk0b08zU08xMDdkNjFn?oc=5) |
| Bloomberg | Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxQVGNGVTFFc2tDUlB3amdhUXNyQ2RKMFpjbjRJNC1LLXlUV0VJY0tvR1F6a2otUzlMeDlZbFdFQzJmaGZzYjhXekJXZjNTXy1xb0NYUHNfNUN5R2l6UVpBd0h1WEI0Nk5kZnlGbkVMeS1MU1BSVTl3SW11ZzBXR0NWTHZSMTJjZGY2WXMxOVg4MmNadFEzNnZId3VzZlJ4ekRiWmp2b1hGZ2NOVVZDcG53?oc=5) |
| Boehringer Ingelheim | Boehringer announces new oncology partnership with SBP Group | [Source Link](https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTHR3clZ1VURzNVd1V0hES3RHd0RTaC1HLTNmQnpqSTV5Vi1RV2YxTDk5bEUyOFhWREkzYUVhSWFQYmo0Ql91aUtsUEhoaHA0M2ZncWZEOWlHU1F0S2g2TWhPenBETGVqeGRzU0Vrb0lyV1hYa3JEd0UwbVVRR3NNeVYtVDVOOXIxbkFCem83dEM1VG1QVjJ6eE9VejN4ZzJiZXNQSTFBN1o?oc=5) |
| Axios | Boehringer doubles down on China with $7B cancer deal | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxQNVJpYWJIMWVfY3FrdHEtN0RUNHRuVzhaLXdfX3FGSzNEcjc3NW9PcnlZWHRKNzVwTEdqWXQ1cVJOTVVDbkt5Z2pyazFHT1Y0UEJhQ0hBOTJxejllbktXeUw3WUVTanIwN0tONW9sdUJuMjBKMFJwZ1gzYzZneWlJTXJoajROMnk1anlsdkQ2cw?oc=5) |
| Fierce Biotech | Boehringer returns to Sino Biopharma in $7.4B deal for preclinical TCEs, ADCs | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxOcU10a0dLdGRMTEw4UUlJX2VoSHNWNWhSZGp3cER0Z2pFc1RRVmlWR3N6R3dxSE9fYVF6UjdjLXFRTUdLWV8wX2J1Zkk3aV9KblVmRjNCdk5UeTZHRzV0TTBBSkJ6S1BodzYwVTZjdERTRWtpTkkwbnBySmZjSHU2U19UZWF2NFpWSU1WOTVPMnlmc2pockR2NkpCU2F5WXhGNkpGSg?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-04/boehringer-returns-to-sino-biopharma-in-7-4b-deal-for-preclinical-tces-adcs*
